Cybin Applauds TheraPsil’s Advocacy to Bring Psilocybin Therapy to Palliative Care of Canadian Patients

no img

Toronto 07 Aug 2020 /

Canada's leading-edge mushroom life sciences company, is proud to applaud the efforts of TheraPsil, a non-profit coalition that advocates for legal, Special Access Programme (SAP) access to psilocybin therapy for palliative care of Canadians.

Recently, four Canadians battling incurable cancer were approved by the federal Minister of Health, Patty Hajdu, to use psilocybin therapy in the treatment of their end-of-life distress. According to TheraPsil, these four patients mark the first publicly-known individuals to receive a legal exemption from the Canadian Drugs and Substances Act, under Section 56, to access psychedelic therapy. They are also the first known patients to legally use psilocybin since the compound became illegal in Canada in 1974.


“This is a watershed moment for the patients involved who deserve the right to manage their health challenges with dignity,” said Paul Glavine, Co-founder of Cybin. “Everyone at Cybin applauds the efforts of TheraPsil and these brave individuals, and we thank the Minister of Health for her foresight.”


Former Ontario Health Minister and Cybin advisor, Dr. Eric Hoskins, praised Minister Hajdu’s approval. “I am pleased to see this important step towards considering psilocybin as a natural compound with a growing body of experience of therapeutic uses for patients in need, rather than strictly a prohibited substance,” Hoskins said. “I joined Cybin because of their dedication to patients who need and benefit from psilocybin-assisted therapy."

Dr. Jukka Karjalainen, Cybin’s Chief Medical Officer concurs: “This landmark recognition of the benefits of psilocybin is tremendous validation for our sector. Cybin is proud to applaud TheraPsil’s efforts, while continuing to focus on the development of a psilocybin oral film delivery system which will potentially alleviate the burden of pill consumption for seniors and patients in palliative care, who often have difficulty swallowing."


Cybin is a life sciences company advancing mushroom-based psychedelic and nutraceutical products for various psychiatric and neurologic conditions. Cybin is developing technology that seeks to improve bioavailability to achieve the desired effects of psychedelics at lower dosages. Cybin is developing products with new delivery systems and intends to support clinical trials to evaluate efficacy to potentially combat major depressive disorder and addiction and improve cognitive flexibility.


Investors: Rob Kelly – Rob@mattio.comMedia Liaison: Sara Brittany Somerset –